According to Swedish Orphan Biovitrum's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 38.5989. At the end of 2022 the company had a P/E ratio of 31.4.
Year | P/E ratio | Change |
---|---|---|
2022 | 31.4 | 50.57% |
2021 | 20.9 | 35.12% |
2020 | 15.5 | 10.17% |
2019 | 14.0 | -39.53% |
2018 | 23.2 | -14.48% |
2017 | 27.1 | -25.34% |
2016 | 36.3 | -93.87% |
2015 | 593 | -808.97% |
2014 | -83.6 | -57.83% |
2013 | -198 | 108.71% |
2012 | -95.0 | -169.08% |
2011 | 138 | -284.05% |
2010 | -74.7 | -186.12% |
2009 | 86.8 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.